Apeloa Company Limited completed the acquisition of 96% stake in Shandong Hanxing Pharmaceutical Technology Co., Ltd. from Hengdian Group Jiayuan Chemical Co., Ltd.
January 06, 2013 at 11:00 pm
Share
Apeloa Company Limited (SZSE:000739) agreed to acquire 96% stake in Shandong Hanxing Pharmaceutical Technology Co., Ltd. from Hengdian Group Jiayuan Chemical Co., Ltd. in stock on February 8, 2012. In related transactions, Apeloa Company Limited (SZSE:000739) agreed to acquire Zhejiang Apeloa Debang Pharmaceutical Co. from Hengdian Group Holdings Ltd. and Zhejiang Hengdian Imp. & Exp. Co., Ltd., 100% in Zhejiang Apeloa Kangyu Pharmaceuticals Medicinal Materials Co., Ltd. and Zhejiang Apeloa Kangyu Bio-Pharmaceutical Co., Ltd. from Hengdian Group Holdings Ltd. and Hengdian Group Kangyu Pharmaceutical Co., Ltd. and medicine import and export business related assets from Zhejiang Hengdian Imp. & Exp. Co., Ltd. on February 8, 2012. Apeloa will issue 116.85 million shares amounting to CNY 950 million as consideration for all the transactions. The shares subscribed from Apeloa Company in this transaction will have a lock-up period of 36 months upon listing. The transaction was resolved by the Directorate of Apeloa Company. Beijing Kang Da Law Firm acted as legal advisor and Southwest Securities Co., Ltd. acted as financial advisor for Apeloa Company Limited.
Apeloa Company Limited (SZSE:000739) completed the acquisition of 96% stake in Shandong Hanxing Pharmaceutical Technology Co., Ltd. from Hengdian Group Jiayuan Chemical Co., Ltd. on January 7, 2013.
Apeloa Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of Active Pharmaceutical Ingredient (API) intermediates, contract development and manufacturing organization (CDMO), preparations and others, as well as import and export trade. The Company operates three businesses. The API intermediates business mainly includes cephalosporin series, penicillin series, psychiatric series, cardiovascular and cerebrovascular series and veterinary API intermediates series. The CDMO business mainly includes research and development services, commercial human drug projects, commercial veterinary drug projects and other commercial products. The preparation business mainly includes anti-infective, cardiovascular and cerebrovascular, psychiatric and anti-tumor preparation products. The Company mainly operates its businesses in domestic and overseas markets.
Apeloa Company Limited completed the acquisition of 96% stake in Shandong Hanxing Pharmaceutical Technology Co., Ltd. from Hengdian Group Jiayuan Chemical Co., Ltd.
APELOA PHARMACEUTICAL CO.,LTD 
